Table 2.

Treatment and outcomes of patients with adult-onset Still’s disease by age group.

	Younger-onset (n = 36) < 65 years	Elderly onset (n = 26) ≥ 65 years	p
Treatment
GCs	35 (97.2%)	26 (100%)	0.39
Maximal dose (mg/kg/day)	0.88 ± 0.26	0.93 ± 0.29	0.47
GCs pulse therapy	26 (72.2%)	20 (76.9%)	0.67
GCs pulse therapy ≥ 3 times	7 (19.4%)	7 (26.9%)	0.48
Time until GCs dose was halved (days)	60.7 ± 25.3	72.8 ± 53.8	0.26
GCs only	11 (30.6%)	12 (46.2%)	0.20
Methotrexate	12 (33.3%)	6 (23.1%)	0.37
Tacrolimus	6 (16.7%)	2 (7.7%)	0.11
Cyclosporine	13 (36.1%)	12 (46.2%)	0.42
Tocilizumab	8 (22.2%)	7 (26.9%)	0.66
Tumor necrosis factor-α inhibitors	1 (2.8%)	1 (3.8%)	0.81
Plasma exchange	11 (30.6%)	4 (15.4%)	0.16
Infection
Cytomegalovirus	5 (13.9%)	10 (38.5%)	0.025
Others	4 (11.1%)	4 (15.4%)	0.62
Relapse	11 (30.6%)	10 (38.5%)	0.51
Death	1 (2.8%)	2 (7.7%)	0.37

Data are presented as numbers (%) or mean ± standard deviation.

p < 0.05, are represented in bold.

GC glucocorticoid.